KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Depreciation & Amortization - Total (2018 - 2023)

TherapeuticsMD's Depreciation & Amortization - Total history spans 7 years, with the latest figure at $100000.0 for Q4 2023.

  • For Q4 2023, Depreciation & Amortization - Total fell 50.0% year-over-year to $100000.0; the TTM value through Sep 2024 reached $100000.0, down 69.51%, while the annual FY2023 figure was $100000.0, 83.33% down from the prior year.
  • Depreciation & Amortization - Total reached $100000.0 in Q4 2023 per TXMD's latest filing, down from $128000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization - Total ranged from a high of $329000.0 in Q1 2022 to a low of $66556.0 in Q2 2019.
  • Average Depreciation & Amortization - Total over 3 years is $185222.3, with a median of $200000.0 recorded in 2022.
  • Peak YoY movement for Depreciation & Amortization - Total: soared 63.22% in 2019, then tumbled 50.0% in 2023.
  • A 3-year view of Depreciation & Amortization - Total shows it stood at $66556.0 in 2019, then surged by 200.5% to $200000.0 in 2022, then crashed by 50.0% to $100000.0 in 2023.
  • Per Business Quant, the three most recent readings for TXMD's Depreciation & Amortization - Total are $100000.0 (Q4 2023), $128000.0 (Q2 2023), and $200000.0 (Q4 2022).